SABCS 2024: General Session 3

Описание: This session took place starting at 9 a.m. Friday, Dec. 13, 2024.. It was the last of the three general sessions at SABCS 2024.

0:00 Introduction from moderators Hikmat Abdel-Razeq of the King Hussein Cancer Center in Amman, Jordan; and Reshma Jagsi from Emory University in Atlanta, Georgia.
00:37 Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom. "Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy."
11:42 Q&A
11:56 Ian Krop, Yale School of Medicine, New Haven, Connecticut. "ctDNA in Early Breast Cancer: So You Say You Want a Revolution?"
30:36 Nan Chen, University of Chicago Medicine, Chicago, Illinois. "Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer."
39:45 Q&A
46:22 Sherko Kuemmel, German Medical Institute, Berlin, Germany. "(Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.
58:12 Q&A
1:03:18 Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania. "NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer."
1:20:00 Q&A
1:21:10 Zhi-Ming Shao, Fudan University, Shanghai, China. "Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial."
1:32:42 Q&A
1:35:36 Giampaolo Bianchini, Vita-Salute San Raffaele University, Milano, Italy. "Immunotherapy in eTNBC: Is it the end of the beginning?"
1:50:52 Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. "In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss."
1:59:52 Q&A
2:02:02 Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York. "Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer."
2:17:10 Q&A
2:19:04 Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina. "Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer."
2:30:00 Q&A
2:33:17 Fred Howard, University of Chicago Medicine, Chicago, Illinois. "Shaping Breast Cancer Care with Computational Genomics."